Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$29.24 USD
+0.90 (3.18%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $29.22 -0.02 (-0.07%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.24 USD
+0.90 (3.18%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $29.22 -0.02 (-0.07%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth A Momentum B VGM
Zacks News
Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed
by Zacks Equity Research
Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.
Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now
by Zacks Equity Research
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
Here's Why Investors Should Buy Integra LifeSciences Now
by Zacks Equity Research
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
3 Plastic & Reconstructive Surgery Stocks Looking Good
by Zacks Equity Research
Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
by Zacks Equity Research
Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.
Integra Rides High on Product Launches, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.
Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
by Zacks Equity Research
Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.
Integra Closes Codman Buyout, Strengthens Neurosurgery Arm
by Zacks Equity Research
With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.
Integra Divests Assets to Natus, Paves Way for Codman Buyout
by Zacks Equity Research
Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.
Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss
by Zacks Equity Research
Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.
Integra LifeSciences (IART) Up 8.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra LifeSciences to Offer aap's LOQTEQ System in the US
by Zacks Equity Research
Global medical technology major, Integra LifeSciences Holdings Corporation (IART) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker.
Integra Lifesciences Hits 52-Week High on Product Launches
by Zacks Equity Research
Share price of Plainsboro NJ-based Integra Lifesciences Corporation (IART) reached a new 52-week high of $47.50 on May 19, finally closing a tad lower at $47.39.
Integra LifeSciences (IART) Misses Q1 Earnings, Retains View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?
by Zacks Equity Research
We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.
Integra LifeSciences Expands Cadence System Commercially
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.
Integra (IART) Titan Reverse Launch Expands Extremity Line
by Zacks Equity Research
Integra LifeSciences (IART) recently broadened its extremity product line with the launch of its Titan Press-Fit Reverse Shoulder for Fracture.
Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 52 cents in the fourth quarter of 2016, up 18% from the year-ago adjusted number.
Integra LifeSciences at 52-Week High on Deals, View Update
by Zacks Equity Research
Shares of Integra LifeSciences Holdings Corporation (IART), a global leader in medical technology, scaled a new 52-week high of $45.50 on Jan 10, closing a tad lower at $44.90.
Why the P/S Ratio is My Favorite Valuation Metric
by Kevin Matras
This week, Kevin Matras shows how to use the Price to Sales ratio. Highlighted stocks include BECN, CORE, HNI, IART and POST.